Grufity logoGrufity logo

ZTS

155.33USD-2.09(-1.33%)Market Closed

Zoetis Inc

Market Summary

USD155.33-2.09Market Closed
-1.33%

ZTS Stock Price

RSI Chart

Valuation

Market Cap

71.8B

Price/Earnings

34.33

Price/Sales

8.98

Price/Cashflow

36.3

MarketCap/EBT

28.01

Price/Sales

Profitability

EBT Margin

32.05%

Return on Equity

45.63%

Return on Assets

15.18%

Fundamentals

Revenue

Revenue (TTM)

8.0B

Revenue Y/Y

5.34%

Revenue Q/Q

3.32%

Earnings

Earnings (TTM)

2.1B

Earnings Y/Y

3.32%

Earnings Q/Q

-11.09%

Price Action

52 Week Range

124.15247.45
(Low)(High)

Last 7 days

4.9%

Last 30 days

6.8%

Last 90 days

0.5%

Trailing 12 Months

-28.9%

Financial Health

Current Ratio

2.18

Investor Care

Dividend Yield

0.8%

Dividend/Share (TTM)

1.23

Buy Backs (1Y)

1.22%

Diluted EPS (TTM)

4.41

Peers (Alternatives to Zoetis)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
459.8B
96.0B
5.64% 16.86%
24
4.79
5.02% 7.14%
342.0B
29.2B
5.87% 53.25%
60.08
11.76
5.34% 1.02%
266.2B
99.7B
9.09% -0.90%
9.08
2.63
43.92% 53.21%
255.3B
57.2B
10.70% 54.15%
15.4
4.47
35.88% 197.59%
163.4B
46.7B
4.75% 50.97%
24.47
3.5
2.79% 223.53%
MID-CAP
5.5B
4.4B
-19.59% -9.60%
-46.93
1.26
1.80% 57.67%
SMALL-CAP
1.9B
628.4M
27.93% -51.99%
-4.08
3.1
64.35% -18.14%
1.9B
659.0M
9.23% 20.30%
32.36
2.95
16.78% -53.92%
1.5B
-
32.82% -58.59%
-0.54
1.95
-4.11% -144.36%
1.2B
112.7M
16.50% -21.36%
-10.75
7.76
-54.94% 40.20%
1.1B
3.1M
16.81% -54.64%
-3.57
108.75
-77.09% -12.24%
1.0B
23.5M
9.62% 31.13%
-12.31
166.87
243.57% -1.04%
945.9M
373.2M
0.99% -19.37%
4.56
2.34
-0.39% -38.45%
283.2M
49.7M
-11.83% -51.92%
-8.71
5.67
28.95% 32.80%
68.8M
2.6B
-43.99% -88.43%
-0.03
0.02
-13.88% -4855.92%

Financials for Zoetis

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue1.3%7,9957,8917,7767,6167,412
  S&GA Expenses1.7%2,0912,0572,0011,9281,848
Earnings Before Taxes1.3%2,5622,5282,4882,4022,340
Net Income0.8%2,0902,0732,0371,9821,909
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-0.6%13,77013,86013,90013,70514,069
  Current Assets-2.7%6,6516,8376,9306,6827,048
    Cash Equivalents-15.4%2,6523,1353,4853,2743,658
  Inventory7.2%2,2052,0571,9231,8751,802
  Net PPE2.9%2,5592,4872,4222,3382,286
  Goodwill1.3%2,7202,6852,6822,7032,718
Liabilities-0.1%9,1909,2029,3569,0249,717
  Current Liabilities0.6%3,0513,0341,7971,4712,091
.    Short Term BorrowingsInfinity%2--4-
    LT Debt, Current0%1,3501,350--600
    LT Debt, Non Current-0.1%5,2215,2286,5926,5926,592
Shareholder's Equity-1.7%4,5804,6584,5434,6794,350
  Retained Earnings4.9%8,0047,6287,1867,0446,492
  Additional Paid-In Capital1.2%1,0591,0461,0681,0561,044
Accumulated Depreciation2.4%2,1932,1412,0722,1132,064
Shares Outstanding-0.6%469471473473474
Minority InterestNaN%--122
Float-88,374----
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations-6.8%1,9772,1222,2132,2522,161
  Share Based Compensation-1.6%6061585756
Cashflow From Investing-12.5%-577.00-513.00-458.00-493.00-553.00
Cashflow From Financing-15.5%-2,388.00-2,068.00-1,862.00-2,145.00-1,319.00
  Buy Backs30.9%1,208923743545347

Risks

What is the probability of a big loss on ZTS?

35.4%


Probability that Zoetis stock will be more than 20% underwater in next one year

30%


Probability that Zoetis stock will be more than 30% underwater in next one year.

3.1%


Probability that Zoetis stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ZTS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Zoetis was unfortunately bought at previous high price.

Returns

Cumulative Returns on ZTS

19.8%


7-Year Cumulative Returns

17.6%


5-Year Cumulative Returns

10.0%


3-Year Cumulative Returns

What are the long-term rolling returns for ZTS?

FIve years rolling returns for Zoetis.

Which funds bought or sold ZTS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Toroso Investments, LLC
ADDED
2.81
-118,000
927,000
0.04%
2022-11-23
Eagle Bay Advisors LLC
REDUCED
-1.03
-12,195
71,000
0.04%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
4.89
-426,000
4,062,000
0.12%
2022-11-22
IHT Wealth Management, LLC
-
-
301,000
675,000
0.05%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
6,608,000
6,608,000
0.08%
2022-11-22
CVA Family Office, LLC
-
-
-
213,000
0.06%
2022-11-21
Kalos Management, Inc.
-
-
-266,000
-
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-20,417,000
117,333,000
0.20%
2022-11-21
FourThought Financial, LLC
-
-
-173,000
1,446,000
0.21%
2022-11-21
Bray Capital Advisors
-
-
-6,000
41,000
0.01%

1–10 of 46

Latest Funds Activity

Are funds buying ZTS calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own ZTS

Zoetis News

Simply Wall St

Zoetis' (NYSE:ZTS) five-year earnings growth trails the 18% YoY shareholder returns.9 hours ago

Zacks Investment Research

Moneyshow.com

ZTS Fair Value

Recent SEC filings of Zoetis

View All Filings
Date Filed Form Type Document
Nov 16, 2022
8-K
Current Report
Nov 10, 2022
3
Insider Trading
Nov 10, 2022
3
Insider Trading
Nov 10, 2022
424B2
Prospectus Filed
Nov 08, 2022
FWP
Prospectus Filed
Nov 08, 2022
424B3
Prospectus Filed
Nov 03, 2022
8-K
Current Report
Nov 03, 2022
10-Q
Quarterly Report
Oct 25, 2022
8-K
Current Report
Oct 13, 2022
8-K
Current Report

Latest Insider Trading transactions for ZTS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-08-05
Polzer Robert J
ACQUIRED
150,605
87.51
1,721
Executive Vice President
2022-08-05
Polzer Robert J
SOLD
-192,383
171.77
-1,120
Executive Vice President
2022-07-22
Lagano Roxanne
ACQUIRED
173,038
79.8515
2,167
Executive Vice President
2022-07-22
Lagano Roxanne
SOLD
-390,623
180.26
-2,167
Executive Vice President
2022-07-21
PECK KRISTIN C
SOLD
-1,744,020
180
-9,689
Chief Executive Officer
2022-07-21
PECK KRISTIN C
ACQUIRED
353,599
36.4949
9,689
Chief Executive Officer
2022-07-07
PECK KRISTIN C
SOLD
-55,980
180
-311
Chief Executive Officer
2022-07-07
PECK KRISTIN C
ACQUIRED
9,606.79
30.89
311
Chief Executive Officer
2022-06-27
Lagano Roxanne
ACQUIRED
346,076
79.8515
4,334
Executive Vice President
2022-06-27
Lagano Roxanne
SOLD
-758,450
175
-4,334
Executive Vice President

1–10 of 50

Kristin C. Peck
12100
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

ZTS Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Revenue$ 2,002$ 1,990$ 6,040$ 5,809
Costs and expenses:    
Cost of sales6075861,8011,703
Selling, general and administrative expenses5015041,4951,408
Research and development expenses134132391370
Amortization of intangible assets3740115121
Restructuring charges and certain acquisition-related costs69939
Interest expense, net of capitalized interest5356159170
Other (income)/deductions—net(3)4616
Income before provision for taxes on income[1]6676592,0641,982
Provision for taxes on income139107413361
Net income before allocation to noncontrolling interests5285521,6511,621
Less: Net loss attributable to noncontrolling interests(1)0(2)(2)
Net income attributable to Zoetis Inc.$ 529$ 552$ 1,653$ 1,623
Earnings per share attributable to Zoetis Inc. stockholders:    
Basic (in dollars per share)$ 1.13$ 1.16$ 3.52$ 3.42
Diluted (in dollars per share)$ 1.13$ 1.16$ 3.51$ 3.40
Weighted-average common shares outstanding:    
Basic (in shares)467.8474.0470.0474.8
Diluted (in shares)469.1476.3471.6477.1
Dividends paid per common share (in dollars per share)$ 0$ 0$ 0.650$ 0.500
[1]Defined as income before provision for taxes on income.

ZTS Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Assets  
Cash and cash equivalents[1]$ 2,507$ 3,485
Accounts receivable, less allowance for doubtful accounts of $21 in 2022 and $17 in 20211,1891,133
Inventories2,3031,923
Other current assets552389
Total current assets6,5516,930
Property, plant and equipment, less accumulated depreciation of $2,232 in 2022 and $2,072 in 20212,6232,422
Operating lease right of use assets217181
Goodwill2,6922,682
Identifiable intangible assets, less accumulated amortization1,3191,474
Noncurrent deferred tax assets111100
Other noncurrent assets161111
Total assets13,67413,900
Liabilities and Equity  
Short-term borrowings30
Current portion of long-term debt1,3500
Accounts payable373436
Dividends payable0154
Accrued expenses679710
Accrued compensation and related items257392
Income taxes payable8438
Other current liabilities13467
Total current liabilities2,8801,797
Long-term debt, net of discount and issuance costs5,2106,592
Noncurrent deferred tax liabilities256320
Operating lease liabilities186151
Other taxes payable241257
Other noncurrent liabilities239239
Total liabilities9,0129,356
Commitments and contingencies (Note 15)
Stockholders' equity:  
Common stock, $0.01 par value: 6,000,000,000 authorized; 501,891,243 and 501,891,243 shares issued; 466,442,095 and 472,574,090 shares outstanding at September 30, 2022, and December 31, 2021, respectively55
Treasury stock, at cost, 35,449,148 and 29,317,153 shares of common stock at September 30, 2022 and December 31, 2021, respectively(4,139)(2,952)
Additional paid-in capital1,0731,068
Retained earnings8,5337,186
Accumulated other comprehensive loss(809)(764)
Total Zoetis Inc. equity4,6634,543
Noncontrolling interests(1)1
Total equity4,6624,544
Total liabilities and equity$ 13,674$ 13,900
[1]As of September 30, 2022 and December 31, 2021, includes $4 million and $3 million of restricted cash, respectively.